EUCTR2019-002849-38-BE进行中（未招募）1 期
A prospective, active-controlled, randomized, open label, single-center, multiple dose, two-period crossover clinical trial to assess the safety, pharmacodynamics, pharmacokinetics, and preliminary efficacy assessment of a budesonide inhalation solution (AQ001S) compared to a budesonide inhalation suspension (comparator) - BOREAS
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Subjects aged between 18 and 65 years, inclusive.
- •2.Body mass index = 30 kg/m2.
- •3.Documented clinical diagnosis of stable, persistent, asthma for at least 3 months, i.e.:
- •for whom forced expiratory volume in one second (FEV1) = 70% of predicted, and
- •treated with as-needed reliever medication (short-acting beta2-agonist-containing medication) only.
- •4.Subjects who are ICS-naïve for minimum 60 days at Screening Visit.
- •5.Positive methacholine (MCh) challenge test (concentration of MCh provoking an FEV1 fall of 20% [PC20] < 8 mg/ml or dose of MCh provoking an FEV1 fall of 20% [PD20] < 0.2 mg) in the last year.
- •6.Post-bronchodilator FEV1 at least 80% of the predicted, documented in the last year.
- •7.Clinical laboratory test results, 12-lead electrocardiogram (ECG), blood pressure and heart rate (supine) within normal reference range or judged to be not clinically significant by the Investigator.
- •8.Female subjects of childbearing potential should have a negative pregnancy test at Screening Visit.
- •9.Female subjects of childbearing potential using a highly effective method of contraception for at least 28 days and pursuing this contraception during the trial and for 28 days after the last administration of the investigational medicinal product (IMP).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 24
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Current smokers or recent (< 8 weeks) ex-smokers or ex-smokers if > 10 pack-years.
- •2.FEV1 < 70%.
- •3.History of near-fatal asthma and/or intensive care unit admission for asthma symptoms.
- •4.Exacerbations of asthma requiring oral steroids, hospitalization or change in asthma treatment in the previous three months.
- •5.Evidence of symptomatic chronic or acute respiratory infection in the previous 8 weeks.
- •6.Diagnosis of chronic obstructive pulmonary disease (COPD) or bronchiectasis.
- •7.Pulmonary malformations, tuberculosis, cystic fibrosis.
- •8.Untreated oral candidiasis.
- •9.Immunosuppressive treatment, including systemic corticosteroids (e.g., oral, parenteral, ocular, nasal), within 28 days before Screening Visit.
- •10.Unstable or life-threatening cardiac disease
- •11.History or presence of prolonged QT interval (> 470 ms), or any other clinically significant ECG abnormalities as judged by the Investigator based on 12-lead ECG recordings at Screening Visit.
- •12.Diabetes mellitus.
- •13.Neuropsychiatric diseases.
- •14.History or presence of malignancy of any system organ class (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years prior to Screening Visit, regardless of whether there is evidence of local recurrence or metastases.
- •15.History or presence of any other clinically relevant disease of any major system organ class (e.g. cardiovascular, pulmonary, renal, hepatic, gastrointestinal, reproductive, endocrinological, neurological, psychiatric or orthopedic disease) as judged by the Investigator.
研究者
相似试验
进行中（未招募）
不适用
A prospective, randomized, verum controlled, open label, parallel group multi-center phase III clinical trial to demonstrate the superiority of 500 or 250 mg Aspirin® i.v. (BAY 81-8781) treatment versus 300 mg Aspirin® N tablets p.o. (BAY e4465A) in patients with Acute Coronary Syndrome, measured by time dependent thromboxane inhibition - ACUTE: Intravenous Aspirin in the Treatment of ACUTe Coronary SyndromEAcute coronary syndrome (ACS)MedDRA version: 14.1Level: PTClassification code 10051592Term: Acute coronary syndromeSystem Organ Class: 10007541 - Cardiac disordersEUCTR2007-005163-94-DEBayer HealthCare AG264
尚未招募
2 期
A study to evaluate the efficacy and safety of oral Myostaal forte a polyherbal formulation in preventing acute flares in patients suffering from osteoarthritis of kneeCTRI/2019/07/020058Solumiks Herbaceuticals Ltd
进行中（未招募）
不适用
An open-label, controlled, randomized, prospective, between groups, multicenter clinical trial on the efficacy and safety of Fitostimoline (vaginal cream, vaginal suppositories and vaginal solution) and of Tantum Rosa (vaginal cream and vaginal solution) in the treatment of the vaginosis (non specific vaginitis) - NDEUCTR2008-005007-26-ITFARMACEUTICI DAMOR
已完成
3 期
A clinical trial to study the effects of Eperisone SR in patients suffering from acute muscle spasms.CTRI/2010/091/000077Themis Medicare Limited200
已完成
3 期
To evaluate the Safety and Hemostat Efficacy of Absorbable Hemostat PowderCTRI/2021/09/036977ucktin Hainan Biotech Co Ltd360